Denali Therapeutics Says FDA Has Selected DNL126 For Participation In Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics announced that the FDA has selected its investigational enzyme replacement therapy, DNL126, for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics Pilot Program. DNL126 is designed to cross the blood-brain barrier for the potential treatment of MPS IIIA (Sanfilippo syndrome type A).
June 03, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics' DNL126 has been selected by the FDA for a pilot program supporting clinical trials for rare disease therapeutics. This selection could accelerate the development of DNL126, designed to treat MPS IIIA.
The FDA's selection of DNL126 for the pilot program is a significant regulatory milestone that could expedite its clinical development. This positive news is likely to boost investor confidence and positively impact DNLI's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100